Myeloproliferative Neoplasms News

President Joe Biden today announced his intention to appoint oncologist, researcher and educator, W. Kimryn Rathmell, MD, PhD, as director of the NCI.

The FDA approved ivosidenib for treatment of certain adults with relapsed or refractory myelodysplastic syndromes.

The FDA approved momelotinib for treatment of patients with myelofibrosis and anemia regardless of prior myelofibrosis therapy.

Study results presented at Society of Hematologic Oncology Annual Meeting highlight the potential effect that socio-racial characteristics may have on outcomes of patients with primary myelofibrosis.

Several factors contributed to inequities of outcomes among people with hematologic malignancies in the United States, according to findings presented at Society of Hematologic Oncology Annual Meeting.

Healio spoke with David Andrew Sallman, MD, about the importance of increasing awareness of myelodysplastic syndrome

Healio spoke with David Andrew Sallman, MD, about unmet needs in myelodysplastic syndrome.

Healio spoke with David Andrew Sallman, MD, about complications in myelodysplastic syndrome.

Healio spoke with David Andrew Sallman, MD, about treatments in the pipeline and ongoing research in myelodysplastic syndrome.

Healio spoke with David Andrew Sallman, MD, about recent advancements and approvals in myelodysplastic syndrome.